论文部分内容阅读
目的:探讨并研究纤溶系统与纤维蛋白原在不稳定型心绞痛(UA)患者发病中的临床价值。方法:对108例不稳定型心绞痛患者和42稳定型心绞痛(SA)患者体内纤溶酶原激活物抑制剂-1(PAI-1)、组织型纤溶酶原激活剂(t-PA)、纤维蛋白原(FIB)水平进行检测,并与20例正常对照者进行对照,探讨其临床意义。结果:UA患者体内PAI-1、FIB水平明显高于SA患者和正常对照者,UA患者中有心血管事件发生者也明显高于无心血管事件发生者;UA患者体内t-PA水平明显低于SA患者和正常对照者,UA患者中有心血管事件发生者也明显低于无心血管事件发生者。结论:UA患者纤溶系统功能异常和FIB水平升高程度较SA患者更加明显,并且UA患者的心血管事件发生可能与溶系统功能异常和FIB水平升高相关。
Objective: To investigate and study the clinical value of fibrinolytic system and fibrinogen in the pathogenesis of unstable angina pectoris (UA). Methods: The expression of plasminogen activator inhibitor-1 (PAI-1), tissue-type plasminogen activator (t-PA) Fibrin (FIB) levels were detected and compared with 20 normal controls to explore its clinical significance. Results: The levels of PAI-1 and FIB in patients with UA were significantly higher than those in patients with SA and controls. The incidence of cardiovascular events in patients with UA was also significantly higher than those without cardiovascular events. The levels of t-PA in patients with UA were significantly lower than those in patients with SA Patients and controls, UA patients with cardiovascular events were also significantly lower than those without cardiovascular events. CONCLUSIONS: The fibrotic system dysfunction and the level of FIB in patients with UA are more pronounced than those in patients with SA, and the occurrence of cardiovascular events in UA patients may be related to dysfunctions of the lymphatic system and elevated FIB levels.